REG - Oxford Biomedica PLC - OXB Capital Markets Event

Oxford BioMedicaAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260602:nRSB5454Ga&default-theme=true

RNS Number : 5454G  Oxford Biomedica PLC  02 June 2026

 

OXB Capital Markets Event

 

·      OXB to demonstrate how its global, multi-vector CDMO platform is
positioned to capture growth in the cell and gene therapy market

·      Event to highlight OXB's proven track record, leading technical
capabilities, expanded international manufacturing network, deep regulatory
expertise and strong client partnerships

·      Sets out a vision for long-term growth, with an ambition to
achieve revenues of c.£500m in 2030 and a clear path to sustainable
profitability and cash flow generation

 

Oxford, UK - 2 June 2026: OXB (LSE: OXB), a global quality and innovation-led
cell and gene therapy CDMO, will today host a Capital Markets Event for equity
research analysts and institutional investors at the London Stock Exchange
Group (LSEG) offices, 10 Paternoster Square, EC4M 7LS, and online.

 

OXB presentations will be given by Dr. Frank Mathias, Chief Executive Officer,
Dr. Lucinda Crabtree, Chief Financial Officer, Dr. Sebastien Ribault, Chief
Business Officer, Dr. Kyriacos Mitrophanous, Chief Innovation Officer and Dr.
Nick Clarkson, Head of Process Development.

 

Presentation topics will include:

 

·      OXB's Competitive Edge: Driving future delivery through
innovation

·      How OXB Wins: Process development excellence & client-centric
delivery

·      OXB's Commercial Engine: Pipeline, client growth and conversion
performance

·      Financial Execution: Powering sustainable growth and creating
value

 

The event will also include external perspectives from leading industry
voices. Professor Luk H Vandenberghe, Ph.D., of Harvard Medical School, and
co-founder of gene therapy companies GenSight Biologics and Akouos, will
provide an external perspective on the cell and gene therapy landscape and how
specialist manufacturing partners can help deliver success. A fireside chat
with Dr. Arun Das, Chief Business Officer at Cabaletta Bio, will provide a
client perspective on the strategic role OXB plays in helping deliver
life-changing therapies to patients.

 

Dr. Frank Mathias, Chief Executive Officer of OXB, commented: "Cell and gene
therapy is now a credible curative option for many patients across a number of
large therapeutic indications and we are just at the beginning. As such, cell
and gene therapy continues to represent one of the most exciting growth
opportunities in healthcare with specialist manufacturing partners having a
critical role to play in enabling the field to scale. Today's Capital Markets
Event will demonstrate why OXB is uniquely positioned to capture an increasing
share of the viral vector CDMO market. Our differentiated platform, leading
technical capabilities, global manufacturing network and strong client
momentum are enabling us to convert demand into scalable growth, supporting
our long-term financial vision and building a clear path to sustainable
profitability."

 

The presentations will begin at 14:00 BST / 09:00 EDT, with attendees arriving
from 13:30 BST, and finish at 17:00 BST followed by a short drinks reception.

 

Those unable to attend in person can register to view a live webcast of the
Capital Markets Event here (https://brrmedia.news/OXB_CME26) , and a recording
of the event will be available on www.oxb.com (http://www.oxb.com) shortly
after its conclusion.

 

No new information on current trading will be shared at the event.

 

-Ends-

 

Enquiries:

 

OXB:

T: +44 (0) 1865 509 737 / E: ir@oxb.com (mailto:ir@oxb.com)

Sophia Bolhassan, Head of Investor Relations

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Sarah Elton-Farr / Angela Gray

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE 250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCVFLFBQQLFBBQ



            Copyright 2019 Regulatory News Service, all rights reserved